News

Novo Nordisk slides further on US competition, new CEO concerns

Pedersen and Maggie Fick COPENHAGEN (Reuters) -Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts ...
The Motley Fool1mon

Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What ...

Novo Nordisk's share price fell as well on Monday. However, the big pharma stock tumbled only around 5%, reflecting a much more muted impact on its business from scrapping the deal with Hims & ...
CBS News1mon

Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive ...

Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy.
The New York Times2mon

Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs

Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased competition for its ...
The Motley Fool1mon

Novo Nordisk Just Improved Its Weight-Management ... - The Motley Fool

Novo Nordisk dished out an up-front payment of $200 million (not to mention potential milestone payments of up to $1.8 billion) to acquire UBT251, a triple agonist -- that is, a medicine that ...
Reuters2mon

Novo Nordisk ousts CEO after falling behind in weight loss market

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.